Tender Details

Country: USA
Summary: Improving the Nation-S Pandemic Influenza Response Capabilities through Expanding Manufacturing Capability
UST Ref No: 86146468
Deadline: 21 Aug 2023
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: HHS-23-BARDA-NOTICE-mRNA-002
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Description
NOTICE OF INTENT
This serves as notice of the Biomedical Advanced Research & Development Authority-s (BARDA) intent to proceed with the programs as outlined below. This notice in no way commits the Government to proceeding with any solicitation.
Title: Improving the Nation-s pandemic influenza response capabilities through expanding manufacturing capability.
Synopsis: Over the last 20+ years, remarkable strides have been made in improving the Nation-s influenza pandemic preparedness and response capabilities. As part of this effort, BARDA has partnered with numerous domestic influenza vaccine developers to support licensure and/or capacity expansion for three different influenza vaccine manufacturing platforms, namely egg-, cell-, and recombinant protein-based vaccines as well as oil-in-water adjuvant technologies. As part of an ongoing program, BARDA works with these US FDA licensed influenza vaccine manufacturers to produce virus ‘seeds-, manufacture clinical investigational lots, perform clinical safety and immunogenicity trials, and manufacture at commercial scale pandemic influenza vaccines for stockpiling or response. As influenza virus is constantly evolving, these ongoing activities are critical to maintaining a ready response posture.
BARDA also recognizes that having multiple influenza vaccine manufacturing platforms is crucial, as no one platform will necessarily work best in all situations. Therefore, BARDA continues to support development of additional influenza vaccine production platforms. BARDA has previously identified that the mRNA vaccine production platform has characteristics that could complement currently licensed influenza vaccine manufacturing approaches. In particular, mRNA vaccines can be rapidly switched to a new viral strain, as witnessed with the COVID-19 response. This is an important attribute when responding to a new viral strain that emerges and spreads rapidly with little warning. Over the last seve...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Improving the Nation-S Pandemic Influenza Response Capabilities through Expanding Manufacturing Capability - USA Tender

The HEALTH AND HUMAN SERVICES, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for Improving the Nation-S Pandemic Influenza Response Capabilities through Expanding Manufacturing Capability. This tender is published on USARFP under UST Ref No: 86146468 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-08-21.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.